

Simon Hussl · Stefan Boehm

## Functions of neuronal P2Y receptors

Received: 4 March 2006 / Accepted: 6 March 2006 / Published online: 10 May 2006  
© Springer-Verlag 2006

**Abstract** Within the last 15 years, at least eight different G protein-coupled nucleotide receptors, i.e., P2Y receptors, have been characterized by molecular means. While ionotropic P2X receptors are mainly involved in fast synaptic neurotransmission, P2Y receptors rather mediate slower neuromodulatory effects. This P2Y receptor-dependent neuromodulation relies on changes in synaptic transmission via either pre- or postsynaptic sites of action. At both sites, the regulation of voltage-gated or transmitter-gated ion channels via G protein-linked signaling cascades has been identified as the predominant underlying mechanisms. In addition, neuronal P2Y receptors have been found to be involved in neurotoxic and neurotrophic effects of extracellular adenosine 5-triphosphate. This review provides an overview of the most prominent actions mediated by neuronal P2Y receptors and describes the signaling cascades involved.

**Keywords** G proteins · P2Y receptor · Voltage-gated Ca<sup>2+</sup> channel · Voltage-gated K<sup>+</sup> channel · Synaptic transmission

### Introduction

Adenine and uridine nucleotides are present in and released from all different types of cells including neurons and glia cells [9]. Extracellular nucleotides bind to a family of membrane-bound receptors that are named P2 receptors [30] and are converted to other nucleotides or degraded towards nucleosides by a family of ectoenzymes [105]. There are two principal subfamilies of P2 receptors which can be discerned from each other by structural and

functional criteria: P2X-receptors are ligand-gated ion channels composed of three subunits, each having two transmembrane domains [145, 156], and P2Y receptors which belong to the superfamily of G protein-coupled receptors (GPCRs) with seven transmembrane domains [2, 12, 146]. Up to now, seven mammalian P2X receptor subunits (P2X1-7) [145, 184] and eight mammalian P2Y receptor subtypes (P2Y<sub>1,2,4,6,11,12,13,14</sub>) [9, 43, 146, 156] have been characterized by molecular means. In addition, receptors for cysteinyl leukotrienes were reported to mediate actions of extracellular nucleotides, which indicates that some GPCRs may display multimodal ligand specificities [124, 125]. Furthermore, a considerable number of reports have described effects of nucleotides that were obviously mediated by receptors, but the receptors involved, such as the receptor for diadenosine-polyphosphates operating in the brain [128], have not been cloned. This review deals only with genuine P2Y receptors with known molecular correlates.

Originally, signaling via nucleotides was proposed to occur in the transmission between neurons of the autonomic nervous system and smooth muscle cells [29]. Nevertheless, in virtually, all peripheral tissues, even in those hardly innervated by the autonomic nervous system, extracellular nucleotides play important roles in a large number of physiological processes [156]. Accordingly, P2 receptors are widely distributed in a large variety of tissues also including the nervous system, and this applies to P2Y receptors even more than to P2X receptors.

Within the central and peripheral nervous system, both types of receptors display a widespread distribution and subserve a variety of functions in both, glial and neuronal cells. Astrocytes, for example, express some P2X and a larger number of P2Y receptors, activation of which first triggers increases in intracellular Ca<sup>2+</sup> and then leads to long-term changes such as proliferation or cell death [55, 140, 191]. The functions of oligodendrocytes [6] and microglial cells [93] are also controlled by nucleotides acting at P2X and P2Y receptors. Likewise, neurons express both classes of P2 receptors: P2X receptors are mainly involved in fast synaptic transmission, whereas

S. Hussl · S. Boehm (✉)  
Center of Biomolecular Medicine and Pharmacology,  
Institute of Pharmacology, Medical University of Vienna,  
Währingerstrasse 13a,  
Vienna 1090, Austria  
e-mail: stefan.boehm@meduniwien.ac.at  
Tel.: +43-1-427764146  
Fax: +43-1-42779641

P2Y receptors rather mediate slow changes of synaptic transmission and neuronal excitability [31, 91]. In addition, P2 receptors may mediate long-term trophic or toxic effects of nucleotides, such as differentiation, neurite growth, survival, or cell death [42]. This review will only deal with neuronal P2 receptors and will disregard the receptors expressed in glial cells.

While ionotropic receptors are most commonly involved in fast neurotransmission, metabotropic receptors are rather involved in neuromodulation: typically, the activation of heptahelical transmembrane receptors elicits changes in neuronal excitability via heterotrimeric G proteins [95]. Accordingly, neuronal P2X receptors frequently mediate synaptic transmission in response to adenosine triphosphate (ATP) released from presynaptic nerve terminals by vesicle exocytosis [98]. P2Y receptors, however, may be activated not only by ATP, but also by other naturally occurring nucleotides or nucleotide-sugars, such as adenosine diphosphate (ADP), uridine triphosphate (UTP), uridine diphosphate (UDP), and UDP-glucose [1, 94, 166]. Hence, these latter receptors are not only the direct target of ATP; the nucleotide stored in vesicles at the highest concentrations [201], but also of other nucleotides and nucleotide degradation products. Therefore, the activation and functions of neuronal P2Y receptors depend not only on the release of ATP, but also on the presence of ATP degrading enzymes [135]. Whether activated by endogenously released nucleotides or exogenous agonists, neuronal P2Y receptors mediate neuromodulatory changes of neuronal excitability and/or synaptic transmission and control neurodegeneration and regeneration. Below, the most recent findings concerning these three types of effects of P2Y receptor activation in the nervous system are summarized.

---

### Pharmacological characteristics and signaling mechanisms of P2Y receptors

A considerable number of heptahelical receptors sensitive to extracellular nucleotides have been cloned from various species. In accordance with the structural classification of P2 receptors, they were categorized as P2Y receptors and numbered in chronologic order. This led to the description of P2Y<sub>1</sub> through P2Y<sub>15</sub> receptors [92]. However, some of the receptors provided with P2Y receptor numbers were subsequently identified as species homologues of other P2Y receptors or as members of other families of G protein-coupled receptors [124, 125]. Hence, only eight different mammalian subtypes are currently viewed as members of the P2Y receptor family, namely, P2Y<sub>1, 2, 4, 6, 11, 12, 13,</sub> and P2Y<sub>14</sub>. Below, the pharmacological characteristics of these P2Y receptors are shortly summarized. For more details, the reader is referred to excellent reviews that focus on this topic [3, 94, 156, 186].

At P2Y<sub>1</sub> receptors of most species, the typical rank order of agonist potency is 2-MeSADP>2-MeSATP>ADP>ATP with uridine nucleotides being inactive. At P2Y<sub>2</sub> receptors, ATP and UTP are equipotent agonists, and ADP, UDP, or

2-methylthio derivatives have weak or no activity [186]. P2Y<sub>4</sub> receptors are activated by UTP, and the rat and mouse receptors are also activated by ATP, whereas the human receptors are antagonized by ATP [97]. At P2Y<sub>6</sub> receptors, UDP is the most potent agonist and ADP, ATP or UTP are, if at all, only weak agonists [186]. Human P2Y<sub>11</sub> receptors display a rank order of agonist potency of ATP>2-MeSATP>ADP, and the observed agonistic activity of UTP depends on the signaling cascade that is activated by the receptor [192]. The nucleotide selectivity of canine P2Y<sub>11</sub> receptors is 2-MeSATP>ADP>ATP [154]. At P2Y<sub>12</sub> receptors, 2-MeSADP is much more potent an agonist than ADP, and the efficacy of ATP is species-dependent with high intrinsic activity at rat, but not at human, receptors [16, 172]. P2Y<sub>13</sub> receptors are activated by 2-MeSADP, ADP, and ATP, but the rank order of agonist potency is different for human, murine, and rat receptors [66, 121, 199]. The P2Y<sub>14</sub> receptor is sensitive towards various UDP sugars, but not towards adenine or uridine nucleotides [1, 36].

In light of the agonist profiles mentioned above, P2Y receptors can be categorized as receptors for purines (P2Y<sub>1, 11, 12, 13,</sub>), pyrimidines (P2Y<sub>6, 14,</sub>), or both families of nucleotides (P2Y<sub>2, 4,</sub>). Furthermore, these receptors can be classified as receptors preferring nucleoside tri- (P2Y<sub>2, 4, 11</sub>) or diphosphates (P2Y<sub>1, 6, 12, 13, 14</sub>). This latter subdivision is particularly important from a physiological point of view: extracellular nucleotides are released from virtually all cells and rapidly converted by ectoenzymes [105]. This inter-conversion between extracellular nucleotides is also a factor that needs to be kept in mind when P2Y receptors are characterized by agonistic nucleotides. For instance, the triphosphate-selectivity of P2Y<sub>2</sub> and <sub>4</sub> receptors can only be shown when the conversion of nucleoside diphosphates towards triphosphates is prevented [141]. In light of these experimental limitations with endogenous and exogenous agonistic nucleotides, the characterization of P2Y receptors should rather rely on the use of specific antagonists. A large number of compounds have been reported to block P2Y receptors, but only a few of them show sufficient selectivity and can be used to differentiate between various receptor subtypes.

The most widely used P2 receptor antagonists, suramin and reactive blue 2, block not only several P2Y receptor subtypes [186], but also P2X receptors and even unrelated proteins, such as NMDA receptors [150] and anion channels [67]. Other P2Y receptor antagonists, however, are more selective. For instance, adenosine-2'-phosphate-5'-phosphate (A2P5P) and adenosine-3'-phosphate-5'-phosphate (A3P5P) are partial agonists with low efficacy at P2Y<sub>1</sub> receptors [25]. Derivatives thereof, such as *N*<sup>6</sup>-methyldeoxyadenosine 3',5'-biphosphate (MRS 2179) or 2-chloro-*N*<sup>6</sup>-methyldeoxyadenosine 3',5'-biphosphate (MRS 2216) are selective and competitive antagonists at P2Y<sub>1</sub> receptors with nanomolar affinity [139]. The P2Y<sub>12</sub> receptor has been identified as the target of metabolites of the well-known antithrombotic drugs ticlopidine and clopidogrel [81]. ATP derivatives, such as cangrelor (AR-C69931MX), are also antagonists with high affinity at this receptor subtype and were developed for clinical use in

patients with acute coronary syndromes [181]. Unfortunately, this latter agent is not absolutely selective for P2Y<sub>12</sub>, but also blocks P2Y<sub>13</sub> receptors. However, at P2Y<sub>12</sub>, this agent is a competitive, and at P2Y<sub>13</sub>, a noncompetitive antagonist [121]. For P2Y<sub>6</sub> receptors, selective antagonists with nanomolar affinities, such as 1,4-*di*-[(3-isothiocyanato phenyl)-thioureido]butane (MRS 2578), have also been developed [116].

After heterologous expression in nonneuronal cells, all P2Y receptor subtypes were found to mediate increases in inositol phosphates (IPs) or in intracellular Ca<sup>2+</sup>; thus, indicating that they are coupled to phospholipase C (PLC) [137, 156, 198]. With P2Y<sub>1</sub>, <sub>6</sub> and <sub>11</sub> receptors, the receptor-mediated increases in IPs did not involve pertussis toxin-sensitive G proteins, but with P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors, these IP increases were reduced by this bacterial

**Table 1** Distribution of P2Y receptors in the nervous system

Types of neurons	P2Y <sub>1</sub>	P2Y <sub>2</sub>	P2Y <sub>4</sub>	P2Y <sub>6</sub>	P2Y <sub>11</sub>	P2Y <sub>12</sub>	P2Y <sub>13</sub>
Sympathetic	R[32,183] F[32]	R[32,144,183] F[15,144]	R[144] F[15,144]	R[32,144,183] F[15,32,143, 144,183]		R[106] F[106]	R[106]
Parasympathetic	P[162,170]	R[111] P[162] F[48,111]	R[111] P[162]	P[162]		P[162]	
Sensory	R[132,161,163] P[63,71,161,163] F[63,71,161]	R[129,133,163] P[137,161] F[129,137,167, 197,202]	R[163] P[15, 161,163]	R[163]			
Enteric	F[83,117]	P[195]		P[196]		P[196]	
Central							
Amygdala	P[99]			R[131]	R[131]	R[81]	
Basal ganglia	R[131] P[130,170]	R[131]	R[131]	R[131]	R[131]		R[37,66]
Brain stem	P[63]						
Cerebellum	R[8,79] P[8,82,132] F[79,164,165]	R[8]	R[8,79,131] P[79]	R[8,79]	R[131]	R[79]	R[37]
Corpus callosum	R[32]					R[47,81]	R[37]
Cortex	R[32,14,72] P[82,130] F[115,193]	F[193]	R[14]	R[14]		R[168]	R[66]
Globus pallidus	R[131] P[130]			R[131]	R[131]		
Hippocampus	R[148,160] P[78,82,99, 130,131,132,160] F[24,164]	R[160] P[78,160]	R[160] P[160]	R[160] P[160]	R[191,160] P[160]	R[81,160,168] P[160]	R[37]
Hypothalamus	R[131] P[82,99] P[132]	P[153]	R[131]		R[131]		
Medial habenula							
Midbrain	P[82,130]						
Substantia nigra					R[131]	R[81]	R[37]
Subthalamus	P[130]						
Thalamus			R[131]		R[131]	R[81]	R[37]
VTA	P[102] F[102]						

The expression of P2Y receptors was evidenced by the determination of RNA (R), protein (P), and/or functional responses (F)

toxin to various degrees [156]. When P2Y<sub>12,13</sub>, and P2Y<sub>14</sub> receptors were activated, increases in IPs were only detected when the receptors were coexpressed together with either G $\alpha_{16}$  or chimaeric G protein  $\alpha$  subunits, and the actions mediated by these receptors were pertussis toxin-sensitive and thus mediated by inhibitory G proteins [36, 37, 198]. P2Y<sub>11</sub> receptors mediate increases in cyclic AMP in addition to the rises in IPs [38], and the coupling of this receptor subtype to different effector systems displays different agonist sensitivities [192]. P2Y<sub>12</sub> and P2Y<sub>13</sub> receptors mediate a pertussis toxin-sensitive inhibition of adenylyl cyclase [37, 81], and in pertussis toxin-treated cells, P2Y<sub>13</sub> mediates a stimulation of adenylyl cyclase [37].

---

### Distribution of P2Y receptors in the nervous system

Most of the known subtypes of P2Y receptors are expressed in the central nervous system. Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) revealed that P2Y<sub>1</sub> and P2Y<sub>11</sub> mRNA was present in the human brain in large quantities when compared with other tissues, but only low to moderate levels of P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> were detectable [131]. In immunohistochemical stainings of human brain slices, a striking neuronal localization of P2Y<sub>1</sub> receptors was confirmed [130]. In contrast, in-situ hybridizations of human [81] and rat [168] brain sections revealed a mainly glial localization of the P2Y<sub>12</sub> receptor. An RT-PCR analysis detected P2Y<sub>13</sub> mRNA in various regions of the human brain, such as cerebellum, hippocampus, substantia nigra, and thalamus [37].

In the peripheral nervous system, mRNA for all P2Y receptor subtypes except P2Y<sub>11</sub> and P2Y<sub>14</sub> has been found in sympathetic neurons [106, 144, 183]. Sensory neurons, in contrast, were shown to express P2Y<sub>1, 2, 4</sub>, and P2Y<sub>6</sub> [163]. In the intramural parasympathetic ganglia of the cat urinary bladder, the presence of P2Y<sub>1, 2, 4, 6</sub>, and P2Y<sub>12</sub> was revealed by immunohistochemistry [162]. In the enteric nervous system of guinea pigs, evidence for the expression of P2Y<sub>1</sub> [83], P2Y<sub>2</sub> [195], P2Y<sub>6</sub>, and P2Y<sub>12</sub> [196] receptors has been obtained. However, there is no evidence for a neuronal localization of P2Y<sub>14</sub>, and the respective mRNA was only found in rat cortical astrocytes [65], where UDP-glucose also elicited a rise in intracellular Ca<sup>2+</sup>. Further details about the distribution of P2Y receptors in the central and peripheral nervous system are given in Table 1.

---

### Functions of P2Y receptors in neurons

Many neuronal functions are similar or even identical to those of other cells, but there is one fundamental difference: the principal tasks of neurons are to receive, modify, and transmit messages. Whether this flow of information occurs intracellularly within one neuron or extracellularly between different neurons, it always

depends on electrical activity provided by ligand- and voltage-gated ion channels. Accordingly, changes in the responsiveness of a neuron are most frequently brought about by alterations in the opening and closure of ion channels, and such effects are in most instances mediated by heptahelical transmembrane receptors linked to G proteins [95]. Therefore, this review first deals with the modulation of neuronal ion channels via P2Y receptors. Apart from changes in the intrinsic electrical properties of a neuron, the major consequences of modified channel gating are alterations in synaptic transmission. Hence, a second focus of P2Y receptor functions described in this study is the pre- and postsynaptic modulation of synaptic transmission via P2Y receptors. Finally, P2Y receptors have been found to mediate trophic as well as degenerative effects of nucleotides on neurons.

### Regulation of ion channels via P2Y receptors

P2Y receptors have been found to control a large variety of neuronal ion channels including voltage-activated Ca<sup>2+</sup> and K<sup>+</sup> channels as well as transmitter-gated ion channels.

#### *Ca<sup>2+</sup> channels*

Voltage-activated Ca<sup>2+</sup> channels are classified by the genes encoding the pore forming  $\alpha_1$  subunits. One can discern between three subfamilies termed Ca<sub>v</sub>1 to Ca<sub>v</sub>3. Members of each of these families contribute to voltage-gated Ca<sup>2+</sup> currents in neurons. Ca<sub>v</sub>1-containing channels mediate L-type currents, whereas those containing Ca<sub>v</sub>2.1 to Ca<sub>v</sub>2.3 mediate P/Q-, N-, and R-type currents. Channels with Ca<sub>v</sub>3 subunits mediate T-type Ca<sup>2+</sup> currents [33]. Channels providing N- and P/Q-type currents are typically involved in excitation secretion coupling in nerve terminals. The other channels, in contrast, are primarily found at somatodendritic regions [33]. Modulation via G protein-coupled receptors has been described for a huge number of neurotransmitters and for all types of voltage-gated Ca<sup>2+</sup> currents [51, 52, 80, 86]. L-type currents are either enhanced or inhibited, and these effects are mostly mediated by diffusible second messengers and protein kinases [51, 52]. In contrast, N and P/Q-type currents are most frequently inhibited via GPCRs, and this inhibition is generally independent of diffusible second messengers and protein kinases [80, 86], even though there are some exceptions to this rule [19, 48]. The pathway excluding diffusible second messengers and protein kinases is membrane-delimited and leads to a voltage-dependent inhibition of the currents, as the inhibition is attenuated by large depolarizations. This type of inhibition is most commonly abolished by pertussis toxin [80], and is based on a direct interaction between G protein  $\beta\gamma$  subunits and Ca<sup>2+</sup> channel proteins [52, 86]. Pathways involving the synthesis of diffusible second messengers most commonly

lead to a voltage-independent reduction of  $\text{Ca}^{2+}$  currents and have been shown to involve  $\alpha$  subunits of the  $G_{q/11}$  protein family [76, 96] and a phospholipase C $\beta$ -dependent depletion of membrane phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) [69, 107].


The first evidence for a regulation of voltage-activated  $\text{Ca}^{2+}$  channels via P2Y receptors was obtained in bovine adrenal chromaffin cells. There, ATP and ADP caused a pertussis toxin-sensitive reduction of current amplitudes [49]. Later on, this effect was reported to be voltage-dependent and sensitive towards reactive blue 2, and to involve an inhibition of N- and P/Q-type calcium channels [41, 70, 152]. Likewise, in rat adrenal chromaffin cells ATP also inhibited voltage-gated  $\text{Ca}^{2+}$  currents in a pertussis toxin-sensitive manner and this effect was again antagonized by reactive blue 2 [110]. An ATP-induced inhibition of  $\text{Ca}^{2+}$  currents was also observed in frog sympathetic neurons [54]. In NG108-15 mouse neuroblastoma  $\times$  rat glioma cells, not only adenine nucleotides, but also UTP and UDP inhibited N-type as well as L-type  $\text{Ca}^{2+}$  channels [56], and the uridine nucleotides were more potent than the adenine nucleotides. The N-type, but not the L-type, channel inhibition was pertussis toxin-sensitive, but it remained unknown whether these two effects were mediated by two different receptor subtypes or by a single receptor coupled to more than one G protein [56].

In several other cases, the nucleotide receptors mediating an inhibition of neuronal  $\text{Ca}^{2+}$  channels were characterized in more detail (Fig. 1). In PC12 cells, for instance, adenosine nucleotides were reported to inhibit voltage-activated  $\text{Ca}^{2+}$  channels via P2Y<sub>12</sub> receptors [103, 104] in a

voltage-dependent and pertussis toxin-sensitive manner [182]. The same receptor was also reported to mediate a voltage-dependent and pertussis toxin-sensitive inhibition of  $\text{Ca}^{2+}$  currents in rat superior cervical ganglion neurons [106]. In hamster submandibular neurons, the same effect was found when P2Y<sub>2</sub> receptors were activated [4]. In rat dorsal root ganglion neurons, P2Y<sub>1</sub> receptors were found to mediate a voltage-dependent inhibition of N-type calcium channels [71]. In HEK 293 cells expressing rabbit Ca<sub>v</sub>2.2  $\alpha_1$  subunits together with  $\beta_1$  and  $\alpha_{2\delta}$  subunits, ADP and ATP were found to mediate a voltage-dependent and pertussis toxin-sensitive inhibition of  $\text{Ca}^{2+}$  currents, and the receptor involved was suggested to be P2Y<sub>13</sub> [194].

However, nucleotides were not only reported to exert inhibitory effects on neuronal  $\text{Ca}^{2+}$  channels. ATP, for instance, has also been found to increase  $\text{Ca}^{2+}$  currents in hippocampal neurons [45], a result also reported for rat cardiac cells [169]. Unfortunately, the receptor subtypes and signaling mechanisms involved in these effects have not been elucidated in detail.

Effects of nucleotides on voltage-activated  $\text{Ca}^{2+}$  channels in neurons have not only been observed with endogenous P2Y receptors, but also after the heterologous expression of recombinant receptors. Based on their findings that UTP activated pertussis toxin-sensitive as well as pertussis toxin-resistant pathways in NG108-15 cells to control various ion channels [56, 59], Alexander Filippov, Eric Barnard, David Brown, and collaborators used rat superior cervical ganglion neurons as an expression system for molecularly defined P2Y receptor subtypes. All of the P2Y receptors that were investigated (P2Y<sub>1,2,4,6,12</sub>) were found to mediate an inhibition of voltage-activated  $\text{Ca}^{2+}$  channels. As expected for a  $G_{i/o}$  coupled receptor, the inhibition of voltage-gated  $\text{Ca}^{2+}$  currents via P2Y<sub>12</sub> receptors was voltage-dependent and pertussis toxin-sensitive, and thus appeared to involve only the membrane-delimited pathway [172]. In contrast, the inhibition of  $\text{Ca}^{2+}$  currents via P2Y<sub>1,2,4</sub> and <sub>6</sub> receptors included two components: a voltage-dependent and pertussis toxin-sensitive membrane-delimited pathway as well as a pertussis toxin-resistant mechanism. The inhibition via P2Y<sub>2</sub> receptors included a voltage-dependent and pertussis toxin-sensitive component, on one hand, and a voltage-independent and pertussis toxin-resistant component, on the other hand [61]. By contrast, when P2Y<sub>6</sub> [62] or P2Y<sub>1</sub> [27, 57] receptors were overexpressed, the pertussis toxin-resistant component appeared to be voltage-dependent because the inhibition of the currents was attenuated by large depolarizing prepulses. Furthermore, the inhibition via P2Y<sub>6</sub> receptors was more pronounced in perforated-patch as compared to whole-cell recordings. Moreover, the inhibition observed in the perforated-patch configuration was hardly altered by pertussis toxin, but in whole-cell recordings, it was reduced by more than one half after treatment with this toxin. Similar results were obtained with overexpressed P2Y<sub>4</sub> receptors [60]: almost no inhibition was observed in the conventional whole-cell mode, but in the perforated-patch recordings, the currents were



**Fig. 1** Mechanisms underlying the regulation of voltage-activated  $\text{Ca}^{2+}$  channels via P2Y receptors. P2Y nucleotide receptors may use at least four different pathways to modulate the functions of neuronal  $\text{Ca}^{2+}$  channels: (1) Activation of P2Y receptors coupled to pertussis toxin-sensitive  $G_{i/o}$  proteins sets  $\beta\gamma$  subunits free which directly interact with pore-forming  $\text{Ca}^{2+}$  channel proteins. This interaction is voltage-dependent (i.e., attenuated by large depolarizations), but generally independent of additional enzymes or second messengers. (2) However, in some cases [e.g. 60], this mechanism may also require a soluble cofactor in addition to the membrane-associated G proteins. (3) Some P2Y receptors may also mediate such a voltage-dependent inhibition of  $\text{Ca}^{2+}$  currents via pertussis toxin-insensitive G proteins [62]. (4) Activation of P2Y receptors linked to pertussis toxin-insensitive  $G_{q/11}$  proteins initiates a signal cascade that involves diffusible second messengers and mediates a voltage-independent inhibition of  $\text{Ca}^{2+}$  currents [60]. For other  $G_{q/11}$ -coupled receptors (e.g., M1 muscarinic or B2 bradykinin), this pathway was found to involve an activation of phospholipase C and a depletion of membrane phosphatidylinositol 4,5-bisphosphate [69, 107]

reduced by about 50% in a pertussis toxin-sensitive and voltage-dependent manner. These findings indicate that even the membrane-delimited, PTX-sensitive pathway may require a soluble cofactor, and that a modulation of voltage-gated  $\text{Ca}^{2+}$  currents should be investigated in both, the perforated-patch and the whole-cell configuration of the patch clamp technique. Recently, the inhibition of voltage-gated  $\text{Ca}^{2+}$  currents of superior cervical ganglion neurons via endogenous bradykinin receptors was also found to be different when these two experimental techniques were used [107].

### $\text{K}^+$ channels


Aside from voltage-gated  $\text{Ca}^{2+}$  channels, a variety of neuronal  $\text{K}^+$  channels have been found to be modulated by extracellular nucleotides. The superfamily of voltage-dependent  $\text{K}^+$  channels comprises many more members than that of  $\text{Ca}^{2+}$  channels and the  $\text{K}^+$  channels are, in addition, very heterogeneous [73]. Quite a number of different  $\text{K}^+$  channels were reported to be modulated by various neurotransmitters, but the most intensively studied examples of  $\text{K}^+$  channel regulation via GPCRs are inward rectifier (Kir) channels and KCNQ channels which are now classified as  $\text{K}_{\text{v}}7$  family [73]. Many inhibitory neurotransmitters cause hyperpolarizations by activating inwardly rectifying  $\text{K}^+$  currents via receptors linked to pertussis toxin-sensitive G proteins. These effects involve proteins of the Kir3 family and G protein  $\beta\gamma$  subunits [174]. However, the regulation of G protein-coupled inwardly rectifying  $\text{K}^+$  (GIRK) channels does not only depend on  $\beta\gamma$  subunits, but also on other proteins and/or second messengers. G protein  $\alpha$  subunits, for instance, act as donors for  $\beta\gamma$ , on one hand, and directly block GIRK channels [149], on the other hand. Moreover, the kinetics of GIRK channel gating are determined by all three parameters, receptor type, G protein  $\alpha$ , and G protein  $\beta\gamma$  subunits [13]. In addition to G protein subunits, regulators of G protein signaling (RGS) determine the kinetics of GIRK activation [53]. GIRK channels are activated by  $\text{PIP}_2$  [84], and the levels of  $\text{PIP}_2$  are also regulated via G protein-coupled receptors and PLC  $\beta$  [157]. Hence, activation of receptors coupled to  $\text{G}_q$  proteins may also contribute to the regulation of GIRK channels [118]. Finally, activation of Gs coupled receptors may lead to an increase in currents through GIRK channels [136].

Several different neurotransmitters depolarize neurons by reducing M-type  $\text{K}^+$  currents ( $I_{\text{M}}$ ) which are mediated by KCNQ channels [158]. These ion channels are opened in the subthreshold voltage range for action potentials and are completely activated when neurons are further depolarized. Hence, activated KCNQ channels keep neurons polarized, and their closure causes depolarization and leads to increased neuronal excitability [26, 46, 120]. The inhibition of  $I_{\text{M}}$  via GPCRs is most commonly mediated by  $\alpha_q$  subunits of heterotrimeric GTP binding proteins [74] and a reduction in  $\text{PIP}_2$  through an activation of phospholipase C  $\beta$  [75, 177]. In addition, this enzyme mediates the

synthesis of inositol trisphosphate ( $\text{IP}_3$ ), which then liberates  $\text{Ca}^{2+}$  from intracellular stores and cytosolic  $\text{Ca}^{2+}$  concentrations in the sub- to low-micromolar range block  $\text{K}_{\text{M}}$  channels [171] via calmodulin [68].

One of the first examples of a modulation of  $\text{K}^+$  channels by nucleotides was the inhibition of  $I_{\text{M}}$  by UTP [5] and ATP [7] in bullfrog sympathetic neurons. Although the receptors involved in these effects remained unknown at that time, the inhibition of  $I_{\text{M}}$  by nucleotides was shown to be mediated by a G protein [112, 178]. In NG108-15 neuroblastoma  $\times$  glioma hybrid cells, activation of the PLC-linked  $\text{P2Y}_2$  receptor was reported to lead to an inhibition of  $I_{\text{M}}$  [59]. Thereafter, a uridine nucleotide preferring receptor, most likely  $\text{P2Y}_6$ , was found to mediate an inhibition of  $I_{\text{M}}$  in rat superior cervical ganglion neurons [17]. The signaling cascade underlying this effect involved an activation of PLC, generation of  $\text{IP}_3$ , and release of  $\text{Ca}^{2+}$  from intracellular stores [22]. In rat thoracolumbar sympathetic neurons [44], UTP and UDP also reduced  $I_{\text{M}}$ , but only in cultures isolated from 9-12 days old rats and not in cultures obtained from newborn animals. In bullfrog sympathetic neurons, the nucleotide-induced inhibition of  $I_{\text{M}}$  was suggested to be mediated by  $\text{P2Y}_4$  receptors (Fig. 2) [127].

In addition to the inhibition of KCNQ channels, the  $\text{P2Y}$  receptor-mediated modulation of several other neuronal potassium channels has been reported. In several papers, Ikeuchi and Nishizaki described outwardly rectifying potassium currents activated by nucleotides. These currents were found in neurons from various brain regions of the rat, such as striatal neurons [87], inferior colliculus neurons [88], superior colliculus neurons [142], cerebellar neurons [89], and hippocampal neurons [90]. Although the currents



**Fig. 2** Mechanisms underlying the regulation of GIRK and KCNQ channels via  $\text{P2Y}$  receptors.  $\text{P2Y}$  nucleotide receptors may use at least three different pathways to modulate the functions of GIRK and KCNQ channels: (1) Activation of  $\text{P2Y}$  receptors coupled to pertussis toxin-sensitive  $\text{G}_{i/o}$  proteins sets  $\beta\gamma$  subunits free which directly interact with Kir3 proteins to activate the channels [172]. (2) Activation of  $\text{P2Y}$  receptors linked to pertussis toxin-insensitive  $\text{G}_{q/11}$  proteins leads to the activation of phospholipase C, which uses membrane phosphatidylinositol 4,5-bisphosphate ( $\text{PIP}_2$ ) to synthesize inositol trisphosphate ( $\text{IP}_3$ ) and diacyl glycerol. Via the depletion of  $\text{PIP}_2$ , GIRK channels [84] as well as KCNQ channels [177] are closed. (3) The accumulating  $\text{IP}_3$  liberates  $\text{Ca}^{2+}$  from intracellular stores, and the increase in cytosolic  $\text{Ca}^{2+}$  inhibits KCNQ channels via calmodulin [68]

that were induced by the nucleotides appeared to be the same in all these neurons, the signal transduction mechanisms and the receptor subtypes involved were different. Responses induced by ATP in striatal neurons and by adenosine in superior colliculus and hippocampal neurons involved a diffusible second messenger and protein kinase C. In contrast, the actions of ADP in inferior colliculus neurons were membrane delimited and presumably based on a direct interaction of  $\beta\gamma$  subunits of a pertussis toxin-insensitive G protein with the channel protein. In rat hippocampal neurons, ATP was also found to inhibit a voltage-gated  $K^+$  channel [138]; UTP was as potent as ATP, and ADP and  $\alpha,\beta$ -methylene ATP also inhibited the outward current. In *Xenopus* spinal neurons, an inward rectifier current was found to be inhibited by adenine and uridine nucleotides [28]. There, a majority of the neurons responded to ADP, but not to ATP or UTP, and the authors speculated about the presence of two different P2Y receptor subtypes, one mediating the effects of the triphosphates and the other one mediating the effects of ADP.

The modulation of potassium channels by nucleotides has also been investigated after the heterologous expression of P2Y receptors, and the channels that were assessed most frequently were the KCNQ channels and the GIRKs (Fig. 2). Again, the receptors were expressed most frequently in rat superior cervical ganglion neurons; activation of the  $G_{q/11}$ -coupled receptors P2Y<sub>1,2,4</sub> and P2Y<sub>6</sub> led to an inhibition of  $I_M$  in a pertussis toxin-resistant manner [27, 60–62]. However, when the P2Y<sub>12</sub> receptor was expressed in these neurons, no inhibition of  $I_M$  by nucleotides could be observed [172]. When rat GIRK1 and GIRK2 (Kir3.1 and 3.2 subunits) were coexpressed with P2Y<sub>12</sub>, 2MeSADP, and 2MeSATP, two appropriate agonists, evoked  $K^+$  currents through GIRK channels. This result agrees with the general concept that  $G_{i/o}$  coupled receptors mediate an activation of GIRK channels. Unexpectedly, the  $G_{q/11}$ -linked P2Y<sub>1</sub> receptor, when coexpressed with Kir3.1 and 3.2 subunits, also mediated a pertussis toxin-sensitive activation of GIRK. This further supports the idea that a single P2Y receptor may couple to multiple types of G proteins. However, with P2Y<sub>1</sub>, the fast activation was followed by a slower but almost complete inactivation of the current in the continuing presence of the agonist [172]. Such a slow inhibition, but no activation, of recombinant GIRK channels in superior cervical ganglion neurons was also observed when P2Y<sub>4</sub> or P2Y<sub>6</sub> receptors were coexpressed with GIRK channels and subsequently activated. These latter effects were pertussis toxin-insensitive and involved  $\alpha_q$  subunits of G proteins [58]. Similarly, when mouse P2Y<sub>2</sub> receptors were coexpressed together with GIRK channels in *Xenopus* oocytes, ATP and UTP activated  $K^+$  currents in a pertussis toxin-sensitive manner [134]. Furthermore, P2Y<sub>2</sub> receptor activation did not only induce GIRK currents, but also led to a subsequent inhibition via a  $Ca^{2+}$ - and PLC-dependent mechanism [119].

### Transmitter-gated ion channels

Although a large number of transmitter-gated ion channels are known, only a few of them were found to be regulated via P2Y receptors. One prominent example is the glutamatergic *N*-methyl-D-aspartate (NMDA) receptor, which is also controlled by other GPCRs. The activation of muscarinic acetylcholine receptors, for instance, has been shown to enhance NMDA receptor currents via protein kinase C and nonreceptor tyrosine kinase [113]. In contrast, D<sub>2</sub>-like dopamine receptors reduce currents through NMDA receptors via transactivation of receptor tyrosine kinases [100]. In addition, D<sub>1</sub> dopamine receptors were found to directly interact with NMDA receptors [109]. Adenine and uridine nucleotides were reported to enhance currents elicited by NMDA in layer V pyramidal neurons of the rat prefrontal cortex. This effect was most likely mediated by P2Y<sub>2</sub> receptors [193]. In contrast, activation of P2Y<sub>1</sub> receptors inhibited currents through the NMDA receptors [115] in the very same cells. In addition, ATP was found to inhibit NMDA receptors independently of P2Y receptors; this effect involved a direct binding of the nucleotide to the glutamate-binding site of the NR2B subunit of NMDA receptors [147].

Another transmitter-gated ion channel that was found to be modulated by nucleotides is the vanilloid receptor 1 (VR1). In rat dorsal root ganglion neurons, capsaicin-evoked currents through VR1 were enhanced by nucleotides [179]. This potentiation was abolished by a protein kinase C inhibitor, and mimicked by phorbol esters. These results indicated that a P2Y receptor linked to protein kinase C via  $G_{q/11}$  proteins was involved, and the P2Y<sub>1</sub> receptor was considered to be the most likely candidate. However, the ATP-induced potentiation was also observed in dorsal root ganglion neurons of P2Y<sub>1</sub> receptor-deficient mice [133], and rat dorsal root ganglion neurons were found to coexpress VR1 and P2Y<sub>2</sub> mRNA, but not P2Y<sub>1</sub> mRNA. Moreover, UTP was reported to be as potent an agonist as ATP, and suramin (which blocks P2Y<sub>2</sub> but not P2Y<sub>4</sub>) abolished the potentiation of VR1 by UTP. Therefore, it was concluded that P2Y<sub>2</sub> receptors mediated the facilitatory effects of nucleotides on VR<sub>1</sub> in mouse and rat dorsal root ganglion neurons [133].

A third family of transmitter-gated ion channels regulated via P2Y receptors are the ATP-gated P2X receptors. Again in rat dorsal root ganglion neurons, the activation of P2Y<sub>1</sub> receptors was reported to modulate P2X<sub>3</sub> receptors via pertussis toxin-insensitive G proteins, but in this case, currents were reduced [72] instead of enhanced. In contrast, when P2Y<sub>1</sub> or P2Y<sub>2</sub> receptors were coexpressed with the P2X<sub>1</sub> receptor in *Xenopus* oocytes, their activation caused a significant potentiation of the P2X receptor-mediated current [185].

---

### Regulation of synaptic transmission

Synaptic transmission requires the release of transmitters from presynaptic nerve terminals and the ensuing activa-

tion of postsynaptic receptors by the released transmitters. Accordingly, synaptic transmission can be modulated either by changes in the presynaptic release or by changes in either the excitability of the postsynaptic membrane or in the signaling capabilities of the postsynaptic receptors. In both cases, the regulation of synaptic transmission via P2Y receptors relies most commonly on the modulation of ion channels as described above. Voltage-activated  $\text{Ca}^{2+}$  channels, in particular N- and P/Q-type channels, are located at presynaptic nerve terminals and link invading action potentials to transmembrane  $\text{Ca}^{2+}$  influx and concomitant vesicle exocytosis. As a consequence, the modulation of these ion channels via GPCRs leads to changes in transmitter release [175]. The waveforms of presynaptic action potentials are shaped by voltage-activated and  $\text{Ca}^{2+}$ -dependent  $\text{K}^+$  channels, and the modulation of these channels via GPCRs can also lead to changes in vesicle exocytosis [50, 123]. In contrast, inwardly rectifying  $\text{K}^+$  channels such as GIRKs are hardly present at presynaptic nerve terminals and are generally not involved in the control of transmitter release [114, 123]. With respect to KCNQ channels, contrasting results have been obtained. In peripheral neurons, no evidence could be obtained that these ion channels are involved in action potential-evoked noradrenaline release [101, 108]. However, in central synaptosomes, modulators of these ion channels were found to affect the release of various transmitters [122]. Taken together, the regulation of  $\text{Ca}^{2+}$  channels and  $\text{Ca}^{2+}$ -dependent  $\text{K}^+$  channels via P2Y receptors will preferentially lead to changes in synaptic transmission via a presynaptic modulation of transmitter release, whereas the control of GIRKs and KCNQ channels will rather cause changes in the postsynaptic excitability. And the modulation of transmitter-gated ion channels will mostly cause alterations in the signaling of postsynaptic receptors, unless these ion channels are also located at presynaptic sites. In fact, P2Y receptors were found to mediate nucleotide-dependent changes in synaptic transmission via both, pre- and postsynaptic effects.

In various regions of the central nervous system, nucleotides were found to either inhibit or enhance the release of acetylcholine, dopamine, noradrenaline, serotonin, glutamate, GABA, or glycine via presynaptic receptors. However, in many cases, the receptor subtypes involved in these presynaptic effects of nucleotides were not unequivocally identified. The release-enhancing effects of nucleotides appeared to be mostly mediated by receptors of the P2X family [40]. The inhibitory effects, in contrast, rather involved P2Y receptors as suggested for the release of noradrenaline [190], serotonin [187], and dopamine [180]. In hippocampal neurons, presynaptic P2Y receptors were reported to mediate an inhibition of glutamate, but not of GABA, release [126]. This effect involved pertussis toxin-sensitive G proteins and an inhibition of voltage-activated  $\text{Ca}^{2+}$  currents, but the precise P2Y receptor subtype(s) involved were not identified [200]. In the medial habenula, a presynaptic P2Y<sub>4</sub>-like receptor was shown to enhance glutamate release, whereas a presumed P2Y<sub>2</sub>-like receptor mediated an inhibition [153].

In the peripheral nervous system, the release of acetylcholine or noradrenaline was also reported to be controlled by presynaptic P2X and P2Y receptors [40]. Because ATP and noradrenaline have long been known to be cotransmitters in the sympathetic nervous system, presynaptic P2 receptors have been studied in greatest detail there. First evidence for presynaptic nucleotide receptors in sympathetic neurons has been obtained more than 20 years ago [176]. More recently, agonistic nucleotides were found to reduce, whereas P2 receptor antagonists were found to enhance noradrenaline release from the mouse vas deferens as indication of inhibitory presynaptic P2Y autoreceptors [188]. In numerous other sympathetically innervated tissues, nucleotides were also reported to inhibit transmitter release [18, 21]. The P2Y receptor subtypes involved in these effects remained elusive for quite some time, but evidence has been presented that P2Y<sub>12</sub> and/or P2Y<sub>13</sub> receptors mediated autoinhibition of transmitter release from sympathetic neurons [155]. Most recently, it was the P2Y<sub>12</sub> receptor subtype that was shown to mediate autoinhibition of transmitter release in sympathetic neurons and in the ontogenetically related PC12 cell line. Furthermore, the signaling cascade involved in this effect was found to include pertussis toxin-sensitive G proteins and a voltage-dependent inhibition of voltage-activated  $\text{Ca}^{2+}$  channels [106]. In sensory neurons, P2Y<sub>1</sub> receptor activation was found to reduce synaptic transmission in pain pathways [71] and it also involved an inhibition of voltage-activated  $\text{Ca}^{2+}$  channels [23].

Via effects at postsynaptic sites, nucleotides were also reported to either inhibit or enhance synaptic transmission. In the prefrontal and parietal cortex, for instance, activation of a P2Y<sub>1</sub>-like receptor reduced glutamatergic transmission, but only the component involving NMDA receptors. Furthermore, the receptor mediated an inhibition of depolarizations caused by NMDA, but not of those induced by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid [115]. In sensory neurons, in contrast, the very same receptor subtype was suggested to facilitate touch-induced impulse generation [137], but the underlying mechanisms remained unknown. In this context, the modulation of VR1 via P2Y receptors might be a relevant mechanism [179]. In autonomic neurons, P2Y<sub>1</sub> receptors were also reported to mediate excitatory postsynaptic effects. In the enteric nervous system, excitatory postsynaptic potentials were found to be blocked by a P2Y<sub>1</sub> receptor antagonist. The direct activation of these receptors caused a  $\text{Na}^+$ -dependent increase in membrane conductance, but the precise ionic mechanisms were not further investigated [83]. In postganglionic sympathetic neurons, P2Y receptors also mediated excitatory postsynaptic effects. UTP was found to depolarize sympathetic ganglia and to trigger transmitter release from dissociated sympathetic neurons via receptors different from those activated by ATP [20, 39, 189]. UDP was equipotent to UTP in triggering noradrenaline release [20, 144], and both nucleotides also caused an inhibition of  $I_M$  [17, 144]. The receptor mediating both effects was suggested to be P2Y<sub>6</sub>, but the stimulation of noradrenaline



release did not only involve the inhibition of KCNQ channels, but also an activation of protein kinase C [183].

### Regulation of neurodegeneration and regeneration

Extracellular ATP has been found to be toxic for a variety of mature differentiated neurons, including cerebellar, striatal, and hippocampal neurons. The nucleotide was reported to induce both, apoptotic and necrotic features of degeneration after only a few minutes of exposure and with a time lag of at most 2 h [8]. In accordance with this finding, P2 receptor antagonists were reported to exert protective effects against neuronal cell death elicited by various stimuli in cerebellar granule and hippocampal neurons as well as in PC12 cells [34, 35]. However, the P2 receptors involved were not further characterized, and the neurotoxic effects of ATP appear to be mediated by P2X rather than P2Y receptors [64].

In contrast to the toxic effects described above, extracellular nucleotides may also exert trophic actions in neural development and growth as well as regeneration and proliferation of the nervous system [64]. The underlying mechanisms have been studied most frequently in the pheochromocytoma cell line PC12. Although ATP itself did not affect differentiation of these cells [77], it stimulated the synthesis and release of neuronal (NGF) and fibroblast growth factor (FGF) and synergized with the trophic factors to enhance neurite outgrowth and differentiation [10, 42, 44, 85]. In addition, ATP and NGF promoted survival of PC12 cells after serum deprivation by upregulating the expression of the heat shock proteins HSP70 and HSP90, by preventing the cleavage and activation of caspase-2, and by inhibiting the release of cytochrome C from mitochondria into the cytoplasm [43]. UTP was also found to increase neurite growth and branching in PC12 cells, and this effect was antagonized by PPADS, thus, suggesting that it was at least in part mediated by P2Y receptors [151]. In support of this conclusion, P2Y<sub>2</sub> receptors were shown to colocalize and associate with the NGF receptor tyrosine receptor kinase A (TrkA) upon stimulation with ATP $\gamma$ S and NGF and to mediate an enhanced neurite formation in PC12 cells and dorsal root ganglion neurons. This effect involved an increased sensitivity towards NGF due to the phosphorylation of TrkA and early response kinases (ERKs) [11]. P2 receptor activation was also reported to promote fiber outgrowth in the developing hippocampus [78], but it remained elusive whether this effect was mediated by P2X or P2Y receptors. In addition, extracellular ATP may influence neurite outgrowth in hippocampal neurons by modulating the adhesion mediated by neuronal cell adhesion molecules [173].

### Conclusion

Extracellular nucleotides are ubiquitous signaling molecules in neuronal as well as nonneuronal tissues. In the

nervous system, ATP acts as a fast synaptic transmitter via ionotropic P2X receptors [159]. In addition, not only ATP, but various other types of nucleotides act on metabotropic P2Y receptors to mediate slow neuromodulatory effects as well as trophic or neurodegenerative actions. A large variety of consequences of neuronal P2Y receptor activation are summarized above and they reveal that nucleotides are as multifaceted neurotransmitters as, for instance, glutamate, GABA, acetylcholine, or serotonin. In light of all these actions mediated by neuronal P2Y receptors, one may expect that these receptors will prove to be valuable drug targets as previously exemplified by the P2Y<sub>12</sub> receptor of platelets [181]. In addition, the knowledge of functions of neuronal P2Y receptors may help to explain unexpected effects observed with well-established P2Y receptor ligands, such as the antithrombotic P2Y<sub>12</sub> antagonists ticlopidin or clopidogrel. With the forthcoming development of new P2Y receptor ligands [94], the ongoing elucidation of P2Y receptor functions in neuronal as well as nonneuronal tissues will further gain in importance.

**Acknowledgements** Work in the authors' laboratory is supported by grants from the Austrian Science Fund, FWF (P15797 and P17611), and from the Virologiefonds of the Medical University of Vienna.

### References

1. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA, Weisman GA, Burnstock G (2003) Characterization of the UDP-glucose receptor (re-named here the P2Y<sub>14</sub> receptor) adds diversity to the P2Y receptor family. *Trends Pharmacol Sci* 24:52–55
2. Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther* 64:445–475
3. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA, Weisman GA (2005) The recently orphanized GPR80 (GPR99) proposed to be the P2Y<sub>15</sub> receptor is not a genuine P2Y receptor. *Trends Pharmacol Sci* 26:8–9
4. Abe M, Endoh T, Suzuki T (2003) Extracellular ATP-induced calcium channel inhibition mediated by P1/P2Y purinoceptors in hamster submandibular ganglion neurons. *Br J Pharmacol* 138:1535–1543
5. Adams PR, Brown DA, Constanti A (1982) Pharmacological inhibition of the M-current. *J Physiol* 332:223–262
6. Agresti C, Meomartini ME, Amadio S, Ambrosini E, Volonte C, Aloisi F, Visentin S (2005) ATP regulates oligodendrocyte progenitor migration, proliferation, and differentiation: involvement of metabotropic P2 receptors. *Brain Res Brain Res Rev* 48:157–165
7. Akasu T, Hirai K, Koketsu K (1983) Modulatory actions of ATP on membrane potentials of bullfrog sympathetic ganglion cells. *Brain Res* 258:313–317
8. Amadio S, D'Ambrosi N, Cavaliere F, Murra B, Sancesario G, Bernardi G, Burnstock G, Volonté C (2002) P2 receptor modulation and cytotoxic function in cultured CNS neurons. *Neuropharmacology* 42:489–501
9. Anderson CM, Parkinson FE (1997) Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides. *Trends Pharmacol Sci* 18:387–392

10. Aono K, Nakanishi N, Yamada S (1990) Increase in intracellular  $\text{Ca}^{2+}$  level and modulation of nerve growth factor action on pheochromocytoma PC12h cells by extracellular ATP. *Meikai Daigaku Shigaku Zasshi* 19:221–229
11. Arthur DB, Akassoglou K, Insel PA (2005) P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation. *Proc Natl Acad Sci USA* 102:19138–19143
12. Barnard EA, Burnstock G, Webb TE (1994) G protein-coupled receptors for ATP and other nucleotides: a new receptor family. *Trends Pharmacol Sci* 15:67–70
13. Benians A, Leaney JL, Milligan G, Tinker A (2003) The dynamics of formation and action of the ternary complex revealed in living cells using a G-protein-gated  $\text{K}^+$  channel as a biosensor. *J Biol Chem* 278:10851–10858
14. Bennett GC, Ford APDW, Smith JAM, Emmett CJ, Webb TE, Boarder M (2003) P2Y receptor regulation of cultured rat cerebral cortical cells: calcium responses and mRNA expression in neurons and glia. *Br J Pharmacol* 139:279–288
15. Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, Roppolo JR, Ford AP, de Groat WC, Burnstock G (2004) Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. *Am J Physiol Renal Physiol* 287:1084–1091
16. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK (2003) Purification and functional reconstitution of the human P2Y12 receptor. *Mol Pharmacol* 64:1210–1216
17. Boehm S (1998) Selective inhibition of M-type potassium channels in rat sympathetic neurons by uridine nucleotide preferring receptors. *Br J Pharmacol* 124:1261–1269
18. Boehm S (2003) Signaling via nucleotide receptors in the sympathetic nervous system. *Drug News Perspect* 16:141–148
19. Boehm S, Huck S, Freissmuth M (1996) Involvement of a phorbol ester-insensitive protein kinase C in the  $\alpha$ 2-adrenergic inhibition of voltage-gated calcium current in chick sympathetic neurons. *J Neurosci* 16:4596–4603
20. Boehm S, Huck S, Illes P (1995) UTP- and ATP-triggered transmitter release from rat sympathetic neurones via separate receptors. *Br J Pharmacol* 116:2341–2343
21. Boehm S, Kubista H (2002) Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. *Pharmacol Rev* 54:43–99
22. Bofill-Cardona E, Vartian N, Nanoff C, Freissmuth M, Boehm S (2000) Two different signaling mechanisms involved in the excitation of rat sympathetic neurons by uridine nucleotides. *Mol Pharmacol* 57:1165–1172
23. Borvendeg SJ, Gerevich Z, Gillen C, Illes P (2003) P2Y receptor-mediated inhibition of voltage-dependent  $\text{Ca}^{2+}$  channels in rat dorsal root ganglion neurons. *Synapse* 47:159–161
24. Bowser DN, Khakh BS (2004) ATP excites interneurons and astrocytes to increase synaptic inhibition in neuronal networks. *J Neurosci* 24:8606–8620
25. Boyer JL, Romero-Avila T, Schachter JB, Harden TK (1996) Identification of competitive antagonists of the P2Y1 receptor. *Mol Pharmacol* 50:1323–1329
26. Brown DA (1983) Slow cholinergic excitation—a mechanism for increasing neuronal excitability. *Trends Neurosci* 6:302–307
27. Brown DA, Filippov AK, Barnard EA (2000) Inhibition of potassium and calcium currents in neurones by molecularly-defined P2Y receptors. *J Auton Nerv Syst* 81:31–36
28. Brown P, Dale N (2002) Modulation of  $\text{K}^+$  currents in *Xenopus* spinal neurons by p2y receptors: a role for ATP and ADP in motor pattern generation. *J Physiol* 540:843–850
29. Burnstock G (1972) Purinergic nerves. *Pharmacol Rev* 24:509–581
30. Burnstock G (1997) The past, present and future of purine nucleotides as signalling molecules. *Neuropharmacology* 36:1127–1139
31. Burnstock G (2003) Purinergic receptors in the nervous system. *Curr Top Membr* 54:307–368
32. Calvert JA, Atterbury-Thomas AE, Leon C, Forsythe ID, Gachet C, Evans RJ (2004) Evidence for P2Y1, P2Y2, P2Y6 and atypical UTP-sensitive receptors coupled to rises in intracellular calcium in mouse cultured superior cervical ganglion neurons and glia. *Br J Pharmacol* 143:525–532
33. Catterall WA, Striessnig J, Snutch TP, Perez-Reyes E (2003) International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. *Pharmacol Rev* 55:579–581
34. Cavaliere F, D'Ambrosi N, Ciotti MT, Mancino G, Sancsario G, Bernardi G, Volonte C (2001a) Glucose deprivation and chemical hypoxia: neuroprotection by P2 receptor antagonists. *Neurochem Int* 38:189–197
35. Cavaliere F, D'Ambrosi N, Sancsario G, Bernardi G, Volonté C (2001b) Hypoglycaemia-induced cell death: features of neuroprotection by the P2 receptor antagonist basilen blue. *Neurochem Int* 38:199–207
36. Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, Trill J, Swift A, Aiyar N, Taylor P, Vawter L, Naheed S, Szekeres P, Hervieu G, Scott C, Watson JM, Murphy AJ, Duzic E, Klein C, Bergsma DJ, Wilson S, Livi GP (2000) A G protein-coupled receptor for UDP-glucose. *J Biol Chem* 275:10767–10771
37. Communi D, Gonzalez NS, Dethoux M, Brezillon S, Lannoy V, Parmentier M, Boeynaems JM (2001) Identification of a novel human ADP receptor coupled to G(i). *J Biol Chem* 276:41479–4185
38. Communi D, Govaerts C, Parmentier M, Boeynaems JM (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. *J Biol Chem* 272:31969–1973
39. Connolly GP, Harrison PJ, Stone TW (1993) Action of purine and pyrimidine nucleotides on the rat superior cervical ganglion. *Br J Pharmacol* 110:1297–1304
40. Cunha RA, Ribeiro JA (2000) ATP as a presynaptic modulator. *Life Sci* 68:119–137
41. Currie KP, Fox AP (1996) ATP serves as a negative feedback inhibitor of voltage-gated  $\text{Ca}^{2+}$  channel currents in cultured bovine adrenal chromaffin cells. *Neuron* 16:1027–1036
42. D'Ambrosi N, Murra B, Cavaliere F, Amadio S, Bernardi G, Burnstock G, Volonte C (2001) Interaction between ATP and nerve growth factor signalling in the survival and neuritic outgrowth from PC12 cells. *Neuroscience* 108:527–534
43. D'Ambrosi N, Murra B, Vacca F, Volonte C (2004) Pathways of survival induced by NGF and extracellular ATP after growth factor deprivation. *Prog Brain Res* 146:93–100
44. D'Ambrosi N, Cavaliere F, Merlo D, Milazzo L, Mercanti D, Volonté C (2000) Antagonists of P2 receptor prevent NGF-dependent neurogenesis in PC12 cells. *Neuropharmacology* 39:1083–1094
45. Dave S, Mogul DJ (1996) ATP receptor activation potentiates a voltage-dependent Ca channel in hippocampal neurons. *Brain Res* 715:208–216
46. Delmas P, Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. *Nat Rev Neurosci* 6:850–862
47. Deng G, Matute C, Kumar CK, Fogarty DJ, Miledi R (1998) Cloning and expression of a P2y purinoceptor from the adult bovine corpus callosum. *Neurobiol Dis* 5:259–270
48. Diverse-Pierluissi M, Dunlap K (1993) Distinct, convergent second messenger pathways modulate neuronal calcium currents. *Neuron* 10:753–760
49. Diverse-Pierluissi M, Dunlap K, Westhead EW (1991) Multiple actions of extracellular ATP on calcium currents in cultured bovine chromaffin cells. *Proc Natl Acad Sci USA* 88:1261–1265
50. Dodson PD, Forsythe ID (2004) Presynaptic  $\text{K}^+$  channels: electrifying regulators of synaptic terminal excitability. *Trends Neurosci* 27:210–217
51. Dolphin AC (1999) L-type calcium channel modulation. *Adv Second Messenger Phosphoprotein Res* 33:153–177

52. Dolphin AC (2003) G protein modulation of voltage-gated calcium channels. *Pharmacol Rev* 55:607–627
53. Doupnik CA, Davidson N, Lester HA, Kofuji P (1997) RGS proteins reconstitute the rapid gating kinetics of gbetagamma-activated inwardly rectifying K<sup>+</sup> channels. *Proc Natl Acad Sci USA* 94:10461–10466
54. Elmslie KS (1992) Calcium current modulation in frog sympathetic neurones: multiple neurotransmitters and G proteins. *J Physiol* 451:229–246
55. Fields RD, Stevens B (2000) ATP: an extracellular signaling molecule between neurons and glia. *Trends Neurosci* 23:625–633
56. Filippov AK, Brown DA (1996) Activation of nucleotide receptors inhibits high-threshold calcium currents in NG108-15 neuronal hybrid cells. *Eur J Neurosci* 8:1149–1155
57. Filippov AK, Brown DA, Barnard EA (2000) The P2Y<sub>1</sub> receptor closes the N-type Ca<sup>2+</sup> channel in neurones, with both adenosine triphosphates and diphosphates as potent agonists. *Br J Pharmacol* 129:1063–1066
58. Filippov AK, Fernandez-Fernandez JM, Marsh SJ, Simon J, Barnard EA, Brown DA (2004) Activation and inhibition of neuronal G protein-gated inwardly rectifying K<sup>(+)</sup> channels by P2Y nucleotide receptors. *Mol Pharmacol* 66:468–477
59. Filippov AK, Selyanko AA, Robbins J, Brown DA (1994) Activation of nucleotide receptors inhibits M-type K current [IK(M)] in neuroblastoma × glioma hybrid cells. *Pflugers Arch* 429:223–230
60. Filippov AK, Simon J, Barnard EA, Brown DA (2003) Coupling of the nucleotide P2Y<sub>4</sub> receptor to neuronal ion channels. *Br J Pharmacol* 138:400–406
61. Filippov AK, Webb TE, Barnard EA, Brown DA (1998) P2Y<sub>2</sub> nucleotide receptors expressed heterologously in sympathetic neurones inhibit both N-type Ca<sup>2+</sup> and M-type K<sup>+</sup> currents. *J Neurosci* 18:5170–5179
62. Filippov AK, Webb TE, Barnard EA, Brown DA (1999) Dual coupling of heterologously-expressed rat P2Y<sub>6</sub> nucleotide receptors to N-type Ca<sup>2+</sup> and M-type K<sup>+</sup> currents in rat sympathetic neurones. *Br J Pharmacol* 126:1009–1017
63. Fong AY, Krstew EV, Barden J, Lawrence AJ (2002) Immunoreactive localisation of P2Y<sub>1</sub> receptors within the rat and human nodose ganglia and rat brainstem: comparison with [alpha 33P]deoxyadenosine 5'-triphosphate autoradiography. *Neuroscience* 113:809–823
64. Franke H, Illes P (2006) Involvement of P2 receptors in the growth and survival of neurons in the CNS. *Pharmacol Ther* 109:297–324
65. Fumagalli M, Brambilla R, D'Ambrosi N, Volonte C, Matteoli M, Verderio C, Abbracchio MP (2003) Nucleotide-mediated calcium signaling in rat cortical astrocytes: role of P2X and P2Y receptors. *Glia* 43:218–203
66. Fumagalli M, Trincavelli L, Lecca D, Martini C, Ciana P, Abbracchio MP (2004) Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y<sub>13</sub> receptor. *Biochem Pharmacol* 68:113–124
67. Galiotta LJ, Falzoni S, Di Virgilio F, Romeo G, Zegarra-Moran O (1997) Characterization of volume-sensitive taurine- and Cl<sup>(-)</sup>-permeable channels. *Am J Physiol* 273:C57–C66
68. Gamper N, Li Y, Shapiro MS (2005) Structural requirements for differential sensitivity of KCNQ K<sup>+</sup> channels to modulation by Ca<sup>2+</sup>/calmodulin. *Mol Biol Cell* 16:3538–3551
69. Gamper N, Reznikov V, Yamada Y, Yang J, Shapiro MS (2004) Phosphatidylinositol 4,5-bisphosphate signals underlie receptor-specific G<sub>q/11</sub>-mediated modulation of N-type Ca<sup>2+</sup> channels. *J Neurosci* 24:10980–10992
70. Gandia L, Garcia AG, Morad M (1993) ATP modulation of calcium channels in chromaffin cells. *J Physiol* 470:55–72
71. Gerevich Z, Borvendeg SJ, Schroder W, Franke H, Wirkner K, Norenberg W, Furst S, Gillen C, Illes P (2004) Inhibition of N-type voltage-activated calcium channels in rat dorsal root ganglion neurons by P2Y receptors is a possible mechanism of ADP-induced analgesia. *J Neurosci* 24:797–807
72. Gerevich Z, Muller C, Illes P (2005) Metabotropic P2Y<sub>1</sub> receptors inhibit P2X<sub>3</sub> receptor-channels in rat dorsal root ganglion neurons. *Eur J Pharmacol* 521:34–38
73. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stuhler W, Wang X (2003) International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. *Pharmacol Rev* 55:583–586
74. Haley JE, Abogadie FC, Delmas P, Dayrell M, Vallis Y, Milligan G, Caulfield MP, Brown DA, Buckley NJ (1998) The alpha subunit of G<sub>q</sub> contributes to muscarinic inhibition of the M-type potassium current in sympathetic neurones. *J Neurosci* 18:4521–4531
75. Haley JE, Abogadie FC, Fernandez-Fernandez JM, Dayrell M, Vallis Y, Buckley NJ, Brown DA (2000) Bradykinin, but not muscarinic, inhibition of M-current in rat sympathetic ganglion neurones involves phospholipase C-beta 4. *J Neurosci* 20:RC105
76. Haley JE, Delmas P, Offermanns S, Abogadie FC, Simon MI, Buckley NJ, Brown DA (2000) Muscarinic inhibition of calcium current and M current in Galpha q-deficient mice. *J Neurosci* 20:3973–3979
77. Heilbronn A, Maienschein V, Carstensen K, Gann W, Zimmermann H (1995) Crucial role of ecto-5'-nucleotidase in differentiation and survival of developing neural cells. *Neuroreport* 7:257–261
78. Heine C, Heimrich B, Vogt J, Wegner A, Illes P, Franke H (2006) P2 receptor-stimulation influences axonal outgrowth in the developing hippocampus in vitro. *Neuroscience* 138:303–311
79. Hervás C, Pérez-Sen R, Miras-Portugal MT (2003) Coexpression of functional P2X and P2Y nucleotide receptors in single cerebellar granule cells. *J Neurosci Res* 73:384–399
80. Hille B (1994) Modulation of ion-channel function by G-protein-coupled receptors. *Trends Neurosci* 17:531–536
81. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature* 409:202–207
82. Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK (2005) [(32)P]2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate [(32)P]MRS2500, a novel radioligand for quantification of native P2Y<sub>1</sub> receptors. *Br J Pharmacol*
83. Hu HZ, Gao N, Zhu MX, Liu S, Ren J, Gao C et al (2003) Slow excitatory synaptic transmission mediated by P2Y<sub>1</sub> receptors in the guinea-pig enteric nervous system. *J Physiol* 550:493–504
84. Huang CL, Feng S, Hilgemann DW (1998) Direct activation of inward rectifier potassium channels by PIP<sub>2</sub> and its stabilization by Gbetagamma. *Nature* 391:803–806
85. Huang CM, Kao LS (1996) Nerve growth factor, epidermal growth factor, and insulin differentially potentiate ATP-induced [Ca<sup>2+</sup>]<sub>i</sub> rise and dopamine secretion in PC12 cells. *J Neurochem* 66:124–130
86. Ikeda SR, Dunlap K (1999) Voltage-dependent modulation of N-type calcium channels: role of G protein subunits. *Adv Second Messenger Phosphoprotein Res* 33:131–151
87. Ikeuchi Y, Nishizaki T (1995a) ATP-evoked potassium currents in rat striatal neurons are mediated by a P2 purinergic receptor. *Neurosci Lett* 190:89–92
88. Ikeuchi Y, Nishizaki T (1995b) The P2Y purinoceptor-operated potassium channel is possibly regulated by the beta gamma subunits of a pertussis toxin-insensitive G-protein in cultured rat inferior colliculus neurons. *Biochem Biophys Res Commun* 214:589–596
89. Ikeuchi Y, Nishizaki T (1996) P2 purinoceptor-operated potassium channel in rat cerebellar neurons. *Biochem Biophys Res Commun* 218:67–71
90. Ikeuchi Y, Nishizaki T, Okada Y (1996) Repetitive applications of ATP potentiate potassium current by Ca<sup>2+</sup>/calmodulin kinase in cultured rat hippocampal neurons. *Neurosci Lett* 203:115–118
91. Illes P, Ribeiro JA (2004) Molecular physiology of P2 receptors in the central nervous system. *Eur J Pharmacol* 483:5–17

92. Inbe H, Watanabe S, Miyawaki M, Tanabe E, Encinas JA (2004) Identification and characterization of a cell-surface receptor, P2Y<sub>15</sub>, for AMP and adenosine. *J Biol Chem* 279:19790–19799
93. Inoue K (2006) The function of microglia through purinergic receptors: neuropathic pain and cytokine release. *Pharmacol Ther* 109:210–226
94. Jacobson KA, Jarvis MF, Williams M (2002) Purine and pyrimidine (P<sub>2</sub>) receptors as drug targets. *J Med Chem* 45:4057–4093
95. Kaczmarek L, Levitan IB (1987) Neuromodulation: the biochemical control of neuronal excitability. Oxford University Press, New York
96. Kammermeier PJ, Ruiz-Velasco V, Ikeda SR (2000) A voltage-independent calcium current inhibitory pathway activated by muscarinic agonists in rat sympathetic neurons requires both G<sub>α</sub>q/11 and G<sub>β</sub>γ. *J Neurosci* 20:5623–5629
97. Kennedy C, Qi AD, Herold CL, Harden TK, Nicholas RA (2000) ATP, an agonist at the rat P2Y<sub>4</sub> receptor, is an antagonist at the human P2Y<sub>4</sub> receptor. *Mol Pharmacol* 57:926–931
98. Khakh BS (2001) Molecular physiology of P2X receptors and ATP signalling at synapses. *Nat Rev Neurosci* 2:165–174
99. Kittner H, Franke H, Fischer W, Schultheis N, Krügel U, Illes P (2003) Stimulation of P2Y<sub>1</sub> receptors causes anxiolytic-like effects in the rat elevated plus-maze: implications for the involvement of P2Y<sub>1</sub> receptor-mediated nitric oxide production. *Neuropsychopharmacology* 28:435–444
100. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH, MacDonald JF (2002) A D<sub>2</sub> class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron* 35:1111–1122
101. Kristufek D, Koth G, Motejlek A, Schwarz K, Huck S, Boehm S (1999) Modulation of spontaneous and stimulation-evoked transmitter release from rat sympathetic neurons by the cognition enhancer linopirdine: insights into its mechanisms of action. *J Neurochem* 72:2083–2091
102. Krügel U, Kittner H, Franke H, Illes P (2001) Stimulation of P<sub>2</sub> receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo. *Neuropharmacology* 40:1084–1093
103. Kubista H, Lechner SG, Wolf AM, Boehm S (2003) Attenuation of the P2Y receptor-mediated control of neuronal Ca<sup>2+</sup> channels in PC12 cells by antithrombotic drugs. *Br J Pharmacol* 138:343–350
104. Kulick MB, von Kugelgen I (2002) P2Y-receptors mediating an inhibition of the evoked entry of calcium through N-type calcium channels at neuronal processes. *J Pharmacol Exp Ther* 303:520–526
105. Lazarowski ER, Boucher RC, Harden TK (2003) Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. *Mol Pharmacol* 64:785–95
106. Lechner SG, Dorostkar MM, Mayer M, Edelbauer H, Pankevych H, Boehm S (2004) Autoinhibition of transmitter release from PC12 cells and sympathetic neurons through a P2Y receptor-mediated inhibition of voltage-gated Ca<sup>2+</sup> channels. *Eur J Neurosci* 20:2917–2928
107. Lechner SG, Hussl S, Schicker KW, Drobny H, Boehm S (2005) Presynaptic inhibition via a phospholipase C- and phosphatidylinositol bisphosphate-dependent regulation of neuronal Ca<sup>2+</sup> channels. *Mol Pharmacol* 68:1387–1396
108. Lechner SG, Mayer M, Boehm S (2003) Activation of M<sub>1</sub> muscarinic receptors triggers transmitter release from rat sympathetic neurons through an inhibition of M-type K<sup>+</sup> channels. *J Physiol* 553:789–802
109. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F (2002) Dual regulation of NMDA receptor functions by direct protein–protein interactions with the dopamine D<sub>1</sub> receptor. *Cell* 111:219–230
110. Lim W, Kim SJ, Yan HD, Kim J (1997) Ca<sup>2+</sup>-channel-dependent and -independent inhibition of exocytosis by extracellular ATP in voltage-clamped rat adrenal chromaffin cells. *Pflugers Arch* 435:34–42
111. Liu D-M, Katnik C, Stafford M, Adams DJ (2000) P2Y purinoceptor activation mobilizes intracellular Ca<sup>2+</sup> and induces a membrane current in rat intracardiac neurones. *J Physiol* 526:287–298
112. Lopez HS, Adams PR (1989) A G protein mediates the inhibition of the voltage-dependent potassium M current by Muscarine, LHRH, substance P and UTP in bullfrog sympathetic neurons. *Eur J Neurosci* 1:529–542
113. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, MacDonald JF (1999) G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. *Nat Neurosci* 2:331–338
114. Luscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA (1997) G protein-coupled inwardly rectifying K<sup>+</sup> channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. *Neuron* 19:687–695
115. Luthardt J, Borvendeg SJ, Sperlagh B, Poelchen W, Wirkner K, Illes P (2003) P2Y<sub>1</sub> receptor activation inhibits NMDA receptor-channels in layer V pyramidal neurons of the rat prefrontal and parietal cortex. *Neurochem Int* 42:161–172
116. Mamedova LK, Joshi BV, Gao ZG, von Kugelgen I, Jacobson KA (2004) Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y<sub>6</sub> nucleotide receptors. *Biochem Pharmacol* 67:1763–1770
117. Man JG de, Winter BY de, Seerden TC, Schepper HU de, Herman AG, Pelckmans PA (2003) Functional evidence that ATP or a related purine is an inhibitory NANC neurotransmitter in the mouse jejunum: study on the identity of P2X and P2Y purinoceptors involved. *Br J Pharmacol* 140:1108–1116
118. Mark MD, Herlitze S (2000) G-protein mediated gating of inward-rectifier K<sup>+</sup> channels. *Eur J Biochem* 267:5830–5836
119. Mark MD, Ruppersberg JP, Herlitze S (2000) Regulation of GIRK channel deactivation by G<sub>α</sub>q and G<sub>α</sub>i/o pathways. *Neuropharmacology* 39:2360–2373
120. Marrison NV (1997) Control of M-current. *Annu Rev Physiol* 59:483–504
121. Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, Boeynaems JM, Gonzalez NS (2003) Pharmacological characterization of the human P2Y<sub>13</sub> receptor. *Mol Pharmacol* 64:104–112
122. Martire M, Castaldo P, D'Amico M, Preziosi P, Annunziato L, Tagliatalata M (2004) M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. *J Neurosci* 24:592–597
123. Meir A, Ginsburg S, Butkevich A, Kachalsky SG, Kaiserman I, Ahdut R, Demigoren S, Rahamimoff R (1999) Ion channels in presynaptic nerve terminals and control of transmitter release. *Physiol Rev* 79:1019–1088
124. Mellor EA, Frank N, Soler D, Hodge MR, Lora JM, Austen KF, Boyce JA (2003) Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT<sub>2R</sub>) by human mast cells: functional distinction from CysLT<sub>1R</sub>. *Proc Natl Acad Sci USA* 100:11589–11593
125. Mellor EA, Maekawa A, Austen KF, Boyce JA (2001) Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. *Proc Natl Acad Sci USA* 98:7964–7969
126. Mendoza-Fernandez V, Andrew RD, Barajas-Lopez C (2000) ATP inhibits glutamate release by acting at P2Y receptors in pyramidal neurons of hippocampal slices. *J Pharmacol Exp Ther* 293:172–179
127. Meng H, Sakakibara M, Nakazawa H, Tokimasa T (2003) Pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid can antagonize the purinoceptor-mediated inhibition of M-current in bullfrog sympathetic neurons. *Neurosci Lett* 337:93–96
128. Miras-Portugal MT, Pintor J, Gualix J (2003) Ca<sup>2+</sup> signalling in brain synaptosomes activated by dinucleotides. *J Membr Biol* 194:1–10

129. Molliver DC, Cook SP, Carlsten JA, Wright DE, McClesley EW (2002) ATP and UTP excite sensory neurons and induce CREB phosphorylation through the metabotropic receptor, P2Y<sub>2</sub>. *Eur J Neurosci* 16:1850–1860
130. Moore D, Chambers J, Waldvogel H, Faull R, Emson P (2000) Regional and cellular distribution of the P2Y<sub>1</sub>(1) purinergic receptor in the human brain: striking neuronal localisation. *J Comp Neurol* 421:374–384
131. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC, Murdock PR (2001) Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. *Biochim Biophys Acta* 1521:107–119
132. Mórán-Jiménez MJ, Matute C (2000) Immunohistochemical localization of the P2Y<sub>1</sub>(1) purinergic receptor in neurons and glial cells of the central nervous system. *Brain Res* 78:50–58
133. Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C, Suzuki N, Inoue K, Gachet C, Noguchi K, Tomimaga M (2003) Possible involvement of P2Y<sub>2</sub> metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. *J Neurosci* 23:6058–6062
134. Mosbacher J, Maier R, Fakler B, Glatz A, Crespo J, Bilbe G (1998) P2Y receptor subtypes differentially couple to inwardly-rectifying potassium channels. *FEBS Lett* 436:104–110
135. Moskvina E, Unterberger U, Boehm S (2003) Activity-dependent autocrine-paracrine activation of neuronal P2Y receptors. *J Neurosci* 23:7479–7488
136. Mullner C, Vorobiov D, Bera AK, Uezono Y, Yakubovich D, Frohwiesser-Steinecker B, Dascal N, Schreibmayer W. (2000) Heterologous facilitation of G protein-activated K<sup>(+)</sup> channels by beta-adrenergic stimulation via cAMP-dependent protein kinase. *J Gen Physiol* 115:547–558
137. Nakamura F, Strittmatter SM (1996) P2Y<sub>1</sub> purinergic receptors in sensory neurons: contribution to touch-induced impulse generation. *Proc Natl Acad Sci USA* 93(19):10465–10470
138. Nakazawa K, Inoue K (1994) ATP reduces voltage-activated K<sup>+</sup> current in cultured rat hippocampal neurons. *Pflugers Arch* 429:143–145
139. Nandan E, Camaioni E, Jang SY, Kim YC, Cristalli G, Herdewijn P, Secrist JA 3rd, Tiwari KN, Mohanram A, Harden TK, Boyer JL, Jacobson KA (1999) Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y<sub>1</sub> receptor antagonists and partial agonists. *J Med Chem* 42:1625–1638
140. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G (1996) Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. *Trends Neurosci* 19:13–18
141. Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden K (1996) Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. *Mol Pharmacol* 50:224–229
142. Nishizaki T, Ikeuchi Y (1996) Adenosine evokes potassium currents by protein kinase C activated via a novel signaling pathway in superior colliculus neurons. *FEBS Lett* 378:1–6
143. Norenberg W, Göbel I, Meyer A, Cox SL, Starke K, Trendelenburg AU (2001) Stimulation of mouse cultured sympathetic neurons by uracil but not adenine nucleotides. *Neuroscience* 103:227–236
144. Norenberg W, von Kugelgen I, Meyer A, Illes P, Starke K (2000) M-type K<sup>+</sup> currents in rat cultured thoracolumbar sympathetic neurones and their role in uracil nucleotide-evoked noradrenaline release. *Br J Pharmacol* 129:709–723
145. North RA (2002) Molecular physiology of P2X receptors. *Physiol Rev* 82:1013–1067
146. North RA, Barnard EA (1997) Nucleotide receptors. *Curr Opin Neurobiol* 7:346–357
147. Ortinau S, Laube B, Zimmermann H (2003) ATP inhibits NMDA receptors after heterologous expression and in cultured hippocampal neurons and attenuates NMDA-mediated neurotoxicity. *J Neurosci* 23:4996–5003
148. Papp L, Balazsa T, Kofalvi A, Erdelyi F, Szabo G, Vizi ES, Sperlagh B (2004) P2X receptor activation elicits transporter-mediated noradrenaline release from rat hippocampal slices. *J Pharmacol Exp Ther* 310:973–980
149. Peleg S, Varon D, Ivanina T, Dessauer CW, Dascal N (2002) G (alpha)(i) controls the gating of the G protein-activated K<sup>(+)</sup> channel, GIRK. *Neuron* 33:87–99
150. Peoples RW, Li C (1998) Inhibition of NMDA-gated ion channels by the P2 purinoceptor antagonists suramin and reactive blue 2 in mouse hippocampal neurones. *Br J Pharmacol* 124:400–408
151. Pooler AM, Guez DH, Benedictus R, Wurtman RJ (2005) Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 cells. *Neuroscience* 134:207–214
152. Powell AD, Teschemacher AG, Seward EP (2000) P2Y purinoceptors inhibit exocytosis in adrenal chromaffin cells via modulation of voltage-operated calcium channels. *J Neurosci* 20:606–616
153. Price GD, Robertson SJ, Edwards FA (2003) Long-term potentiation of glutamatergic synaptic transmission induced by activation of presynaptic P2Y receptors in the rat medial habenula nucleus. *Eur J Neurosci* 17:844–850
154. Qi AD, Zambon AC, Insel PA, Nicholas RA (2001) An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y<sub>11</sub> receptors. *Mol Pharmacol* 60:1375–1382
155. Queiroz G, Talaia C, Goncalves J (2003) ATP modulates noradrenaline release by activation of inhibitory P2Y receptors and facilitatory P2X receptors in the rat vas deferens. *J Pharmacol Exp Ther* 307:809–815
156. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. *Pharmacol Rev* 50:413–492
157. Rebecchi MJ, Pentylala SN (2000) Structure, function, and control of phosphoinositide-specific phospholipase C. *Physiol Rev* 80:1291–1335
158. Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology, and pharmacology. *Pharmacol Ther* 90:1–19
159. Robertson SJ, Ennion SJ, Evans RJ, Edwards FA (2001) Synaptic P2X receptors. *Curr Opin Neurobiol* 11:378–386
160. Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, Cunha RA (2005) Dual presynaptic control by ATP of glutamate release via facilitatory P2X<sub>1</sub>, P2X<sub>2/3</sub>, and P2X<sub>3</sub> and inhibitory P2Y<sub>1</sub>, P2Y<sub>2</sub>, and/or P2Y<sub>4</sub> receptors in the rat hippocampus. *J Neurosci* 25:6286–6295
161. Ruan H-Z, Birder LA, de Groat WC, Tai C, Roppolo J, Buffington CA, Burnstock G (2005a) Localization of P2X and P2Y receptors in dorsal root ganglia of the cat. *J Histochem Cytochem* 53:1273–1282
162. Ruan H-Z, Birder LA, Xiang Z, Chopra B, Buffington T, Tai C, Roppolo JR, de Groat WC, Burnstock G (2005b) Expression of P2X and P2Y receptors in the intramural parasympathetic ganglia of the cat urinary bladder. *Am J Physiol Renal Physiol* (in press)
163. Ruan H-Z, Burnstock G (2003) Localisation of P2Y<sub>1</sub> and P2Y<sub>4</sub> receptors in dorsal root, nodose and trigeminal ganglia of the rat. *Histochem Cell Biol* 120:415–426
164. Safiulina VF, Kasyanov AM, Sokolova E, Cherubini E, Giniatullin R (2005) ATP contributes to the generation of network-driven giant depolarizing potentials in the neonatal rat hippocampus. *J Physiol* 15(565):981–992
165. Saitow F, Murakoshi T, Suzuki H, Konishi S (2005) Metabotropic P2Y purinoceptor-mediated presynaptic and postsynaptic enhancement of cerebellar GABAergic transmission. *J Neurosci* 25:2108–2116
166. Sak K, Webb TE (2002) A retrospective of recombinant P2Y receptor subtypes and their pharmacology. *Arch Biochem Biophys* 397:131–136

167. Sanada M, Yasuda H, Omatsu-Kanbe M, Sango K, Isono T, Matsuura H, Kikkawa R (2002) Increase in intracellular Ca<sup>2+</sup> and calcitonin gene-related peptide release through metabotropic P2Y receptors in rat dorsal root ganglion neurons. *Neuroscience* 111:413–422
168. Sasaki Y, Hoshi M, Akazawa C, Nakamura Y, Tsuzuki H, Inoue K, Kohsaka S (2003) Selective expression of Gi/o-coupled ATP receptor P2Y<sub>12</sub> in microglia in rat brain. *Glia* 44:242–250
169. Scamps F, Vassort G (1994) Pharmacological profile of the ATP-mediated increase in L-type calcium current amplitude and activation of a non-specific cationic current in rat ventricular cells. *Br J Pharmacol* 113:982–986
170. Scheibler P, Pesic M, Franke H, Reinhardt R, Wirkner K, Illes P, Norenberg W (2004) P2X<sub>2</sub> and P2Y<sub>1</sub> immunofluorescence in rat neostriatal medium-spiny projection neurones and cholinergic interneurons is not linked to respective purinergic receptor function. *Br J Pharmacol* 143:119–131
171. Selyanko AA, Brown DA (1996) Intracellular calcium directly inhibits potassium M channels in excised membrane patches from rat sympathetic neurons. *Neuron* 16:151–162
172. Simon J, Filippov AK, Goransson S, Wong YH, Frelin C, Michel AD, Brown DA, Barnard EA (2002) Characterization and channel coupling of the P2Y<sub>12</sub> nucleotide receptor of brain capillary endothelial cells. *J Biol Chem* 277:31390–31400
173. Skladchikova G, Ronn LC, Berezin V, Bock E (1999) Extracellular adenosine triphosphate affects neural cell adhesion molecule (NCAM)-mediated cell adhesion and neurite outgrowth. *J Neurosci Res* 57:207–218
174. Stanfield PR, Nakajima S, Nakajima Y (2002) Constitutively active and G-protein coupled inward rectifier K<sup>+</sup> channels: Kir2.0 and Kir3.0. *Rev Physiol Biochem Pharmacol* 145:47–179
175. Stevens CF (2004) Presynaptic function. *Curr Opin Neurobiol* 14:341–345
176. Stjarne L, Astrand P (1985) Relative pre- and postjunctional roles of noradrenaline and adenosine 5'-triphosphate as neurotransmitters of the sympathetic nerves of guinea-pig and mouse vas deferens. *Neuroscience* 14:929–946
177. Suh BC, Hille B (2002) Recovery from muscarinic modulation of M current channels requires phosphatidylinositol 4,5-bisphosphate synthesis. *Neuron* 35:507–520
178. Tokimasa T, Akasu T (1990) ATP regulates muscarine-sensitive potassium current in dissociated bull-frog primary afferent neurones. *J Physiol* 426:241–264
179. Tominaga M, Wada M, Masu M (2001) Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. *Proc Natl Acad Sci USA* 98:6951–6956
180. Trendelenburg AU, Bultmann R (2000) P2 receptor-mediated inhibition of dopamine release in rat neostriatum. *Neuroscience* 96:249–252
181. van Giezen JJ, Humphries RG (2005) Preclinical and clinical studies with selective reversible direct P2Y<sub>12</sub> antagonists. *Semin Thromb Hemost* 31:195–204
182. Vartian N, Boehm S (2001) P2Y receptor-mediated inhibition of voltage-activated Ca<sup>2+</sup> currents in PC12 cells. *Eur J Neurosci* 13:899–908
183. Vartian N, Moskvina E, Scholze T, Unterberger U, Allgaier C, Boehm S (2001) UTP evokes noradrenaline release from rat sympathetic neurons by activation of protein kinase C. *J Neurochem* 77:876–885
184. Vial C, Roberts JA, Evans RJ (2004a) Molecular properties of ATP-gated P2X receptor ion channels. *Trends Pharmacol Sci* 25:487–493
185. Vial C, Tobin AB, Evans RJ (2004b) G-protein-coupled receptor regulation of P2X<sub>1</sub> receptors does not involve direct channel phosphorylation. *Biochem J* 382:101–110
186. von Kugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. *Pharmacol Ther* (in press)
187. von Kugelgen I, Koch H, Starke K (1997a) P2 receptor-mediated inhibition of serotonin release in rat brain cortex. *Neuropharmacology* 36:1221–1227
188. von Kugelgen I, Kurz K, Starke K (1993) Axon terminal P2-purinoceptors in feedback control of sympathetic transmitter release. *Neuroscience* 56:263–267
189. von Kugelgen I, Norenberg W, Illes P, Schobert A, Starke K (1997b) Differences in the mode of stimulation of cultured rat sympathetic neurons between ATP and UDP. *Neuroscience* 78:935–941
190. von Kugelgen I, Spath L, Starke K (1994) Evidence for P2-purinoceptor-mediated inhibition of noradrenaline release in rat brain cortex. *Br J Pharmacol* 113:815–822
191. Weisman GA, Wang M, Kong Q, Chorna NE, Neary JT, Sun GY, Gonzalez FA, Seye CI, Erb L (2005) Molecular determinants of P2Y<sub>2</sub> nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. *Mol Neurobiol* 31:169–183
192. White PJ, Webb TE, Boarder MR (2003) Characterization of a Ca<sup>2+</sup> response to both UTP and ATP at human P2Y<sub>11</sub> receptors: evidence for agonist-specific signaling. *Mol Pharmacol* 63:1356–1363
193. Wirkner K, Koles L, Thummler S, Luthardt J, Poelchen W, Franke H, Furst S, Illes P (2002) Interaction between P2Y and NMDA receptors in layer V pyramidal neurons of the rat prefrontal cortex. *Neuropharmacology* 42:476–488
194. Wirkner K, Schweigel J, Gerevich Z, Franke H, Allgaier C, Barsoumian EL, Draheim H, Illes P (2004) Adenine nucleotides inhibit recombinant N-type calcium channels via G protein-coupled mechanisms in HEK 293 cells; involvement of the P2Y<sub>13</sub> receptor-type. *Br J Pharmacol* 141:141–151
195. Xiang Z, Burnstock G (2005a) Distribution of P2Y<sub>2</sub> receptors in the guinea pig enteric nervous system and its coexistence with P2X<sub>2</sub> and P2X<sub>3</sub> receptors, neuropeptide Y, nitric oxide synthase and calretinin. *Histochem Cell Biol* 124:379–390
196. Xiang Z, Burnstock G (2005b) Distribution of P2Y<sub>6</sub> and P2Y<sub>12</sub> receptor: their colocalization with calbindin, calretinin and nitric oxide synthase in the guinea pig enteric nervous system. *Histochem Cell Biol* (in press)
197. Xu J, Tse FW, Tse A (2003) ATP triggers intracellular Ca<sup>2+</sup> release in type II cells of the rat carotid body. *J Physiol* 549:739–747
198. Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr. (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. *J Biol Chem* 276:8608–8615
199. Zhang FL, Luo L, Gustafson E, Palmer K, Qiao X, Fan X, Yang S, Laz TM, Bayne M, Monsma F Jr (2002) P2Y<sub>13</sub>: identification and characterization of a novel G<sub>α</sub>hi-coupled ADP receptor from human and mouse. *J Pharmacol Exp Ther* 301:705–713
200. Zhang JM, Wang HK, Ye CQ, Ge W, Chen Y, Jiang ZL (2003) ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. *Neuron* 40:971–982
201. Zimmermann H (1994) Signalling via ATP in the nervous system. *Trends Neurosci* 17:420–426
202. Zimmermann K, Reeh PW, Averbach B (2002) ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE<sub>2</sub> release in isolated rat dura mater. *Pain* 97:259–265